Second. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness.
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024
Project: I-MOVE-plus
Updated at: 29-04-2024